At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 344 enrolled
Drug / intervention
Insulin Glargine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Premixed Insulin Lispro Low-Mixture and Mid-Mixture Regimens With Separate Basal and Bolus Insulin Injections in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Oral Therapy Who Consume Light Breakfast
In Brief
A Phase 4 clinical trial evaluating Insulin Glargine and Insulin Lispro Premix (mid-mixture and low-mixture) for Diabetes Mellitus, Type 2. Completed, enrolled 344 participants across 27 sites in 8 countries.
Detailed Summary
This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCanada, Egypt, India, Mexico, Portugal, Romania, Spain, Turkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionNov 2010
TodayJul 2026
First PostedApr 23, 2008
Enrollment StartApr 1, 2008
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.2 years ago
Interventions
Insulin Glarginedrug
patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
Insulin Lispro Premix (mid-mixture and low-mixture)drug
patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks